- Home
- DVA vs FUTU Comparison
DVA vs FUTU Comparison
Compare DVA & FUTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- FUTU
- Stock Information
- Founded
- DVA 1994
- FUTU 2011
- Country
- DVA United States
- FUTU Hong Kong
- Employees
- DVA N/A
- FUTU N/A
- Industry
- DVA Misc Health and Biotechnology Services
- FUTU Investment Bankers/Brokers/Service
- Sector
- DVA Health Care
- FUTU Finance
- Exchange
- DVA Nasdaq
- FUTU Nasdaq
- Market Cap
- DVA 10.9B
- FUTU N/A
- IPO Year
- DVA 1995
- FUTU 2019
- Fundamental
- Price
- DVA $147.17
- FUTU $121.64
- Analyst Decision
- DVA Hold
- FUTU Strong Buy
- Analyst Count
- DVA 4
- FUTU 4
- Target Price
- DVA $157.00
- FUTU $136.23
- AVG Volume (30 Days)
- DVA 839.6K
- FUTU 2.0M
- Earning Date
- DVA 08-05-2025
- FUTU 08-19-2025
- Dividend Yield
- DVA N/A
- FUTU 1.60%
- EPS Growth
- DVA 14.90
- FUTU 58.31
- EPS
- DVA 10.11
- FUTU 6.00
- Revenue
- DVA $12,968,524,000.00
- FUTU $1,788,948,850.00
- Revenue This Year
- DVA $6.46
- FUTU $48.73
- Revenue Next Year
- DVA $3.24
- FUTU $9.97
- P/E Ratio
- DVA $14.09
- FUTU $20.58
- Revenue Growth
- DVA 5.11
- FUTU 54.51
- 52 Week Low
- DVA $131.76
- FUTU $51.80
- 52 Week High
- DVA $179.60
- FUTU $130.88
- Technical
- Relative Strength Index (RSI)
- DVA 61.95
- FUTU 58.40
- Support Level
- DVA $135.07
- FUTU $119.61
- Resistance Level
- DVA $143.64
- FUTU $126.00
- Average True Range (ATR)
- DVA 2.80
- FUTU 5.15
- MACD
- DVA 0.90
- FUTU 0.29
- Stochastic Oscillator
- DVA 97.16
- FUTU 68.32
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.